Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
Celebrates Indian Independence Day by Honoring the US-India Innovation PartnershipCAMBRIDGE, Mass.--(BUSINESS WIRE)--$HIND--Vyome…
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Announced first patient dosed in the Phase 2b placebo-controlled portion of the…
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025 17:06 ET Â | Source: Taysha Gene Therapies, Inc. DALLAS,…
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
July 25, 2025 16:15 ET Â | Source: Portage Biotech Inc. DOVER, Del.,…
Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in…
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
July 02, 2025 03:00 ET Â | Source: Belite Bio, Inc -Â 500…
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof…
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
June 20, 2025 19:30 ET Â | Source: Structure Therapeutics Inc. SAN FRANCISCO,…
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
June 19, 2025 01:00 ET Â | Source: Addex Therapeutics Strong cash position…